Pioglitazone Therapy of PAX8-PPARγ Fusion Protein Thyroid Carcinoma | Zendy

Thomas J. Giordano | Zendy; Bryan R. Haugen | Zendy; Steven I. Sherman | Zendy; Manisha H. Shah | Zendy; Elaine M. Caoili | Zendy; Ronald J. Koenig | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Pioglitazone Therapy of PAX8-PPARγ Fusion Protein Thyroid Carcinoma

Author(s) -

Thomas J. Giordano,

Bryan R. Haugen,

Steven I. Sherman,

Manisha H. Shah,

Elaine M. Caoili,

Ronald J. Koenig

Publication year - 2018

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - Uncategorized

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2017-02533

Subject(s) - pioglitazone , thyroglobulin , medicine , thyroid , thyroid cancer , thyroid carcinoma , metastasis , cancer , carcinoma , cancer research , endocrinology , oncology , pathology , diabetes mellitus , type 2 diabetes

A subset of thyroid carcinomas expresses an oncogenic paired box 8 (PAX8) and peroxisome proliferator activated receptor γ (PPARγ) fusion protein (PPFP). The PPARγ/PPFP ligand pioglitazone is highly therapeutic in a transgenic mouse model of PPFP thyroid carcinoma, but whether pioglitazone is therapeutic in patients with PPFP thyroid carcinoma is unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research